Cepheid Beats, Raises Outlook - Analyst Blog
July 22 2011 - 3:08AM
Zacks
Cepheid (CPHD) reported EPS of 3 cents during
the second quarter of fiscal 2011, much better than the loss of 3
cents in the year-ago period and the Zacks Consensus Estimate of a
2 cents loss.
Revenues during the quarter increased 31% to $63.6 million,
beating the Zacks Consensus Estimate of $61 million. The upside was
driven by a 42% growth in Clinical segment attributable to strong
sales of reagents and systems. Based on strong revenue growth,
Cepheid was able to improve its bottom line.
Among the different segments, the Clinical segment consisting of
Clinical Systems (up 53% year over year to $13.2 million) and
Clinical Reagents (up 40% to $44.1 million) contributed about 90%
of the total sales during the quarter. Cepheid’s Non-Clinical
business dropped 25% year over year to $6.3 million. Sales from
North America and the international market recorded a
year-over-year increase of 25% and 52%, respectively.
Gross margin on product sales improved to 54% compared with 48%
in the second quarter of 2010. While product sales improved 31%,
cost of products sold increased by only 16% leading to an
improvement in margin.
Operating expenses amounted to $34.7 million, up 37.4% compared
with the year-ago quarter, driven by higher research and
development (37% annually to $13.9 million), sales and marketing
(28.3% to $11.9 million), and general and administrative expenses
(52.3.5% to $8.9 million).
During the quarter, Cepheid’s 148 GeneXpert systems were
installed. In addition, the company placed 38 GeneXpert (58 in the
first quarter) systems as part of its High Burden Developing
Country (HBDC) Program. Including the HBDC systems, a cumulative
total of 2,224 systems have been placed worldwide as of June 30,
2011. At the end of the reported quarter, cash and cash equivalents
were $98.3 million, up from $79.5 million at the end of December
2010.
Raises Outlook
Cepheid raised its outlook for 2011. The company expects to
report revenues of $265–$270 million (previous guidance of
$245–$255 million) and EPS of 8–11 cents (loss of 1 cent to a
profit of 4 cents per share).
CEPHEID INC (CPHD): Free Stock Analysis Report
Zacks Investment Research
Cepheid (NASDAQ:CPHD)
Historical Stock Chart
From Aug 2024 to Sep 2024
Cepheid (NASDAQ:CPHD)
Historical Stock Chart
From Sep 2023 to Sep 2024